WO2016082808A1 - Oral preparation - Google Patents
Oral preparation Download PDFInfo
- Publication number
- WO2016082808A1 WO2016082808A1 PCT/CZ2015/050011 CZ2015050011W WO2016082808A1 WO 2016082808 A1 WO2016082808 A1 WO 2016082808A1 CZ 2015050011 W CZ2015050011 W CZ 2015050011W WO 2016082808 A1 WO2016082808 A1 WO 2016082808A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- units
- methacrylates
- polyoxyethylene
- methacrylamides
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 41
- -1 hydroxyalkyl acrylates Chemical class 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims abstract description 13
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical class CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 12
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 8
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims abstract description 7
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 7
- 150000003926 acrylamides Chemical class 0.000 claims abstract description 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000005395 methacrylic acid group Chemical class 0.000 claims abstract description 3
- 230000003232 mucoadhesive effect Effects 0.000 claims abstract description 3
- 229920000642 polymer Polymers 0.000 claims description 84
- 239000000243 solution Substances 0.000 claims description 38
- 239000000126 substance Substances 0.000 claims description 12
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- KDRNOBUWMVLVFH-UHFFFAOYSA-N 2-methyl-n-(2,2,6,6-tetramethylpiperidin-4-yl)prop-2-enamide Chemical compound CC(=C)C(=O)NC1CC(C)(C)NC(C)(C)C1 KDRNOBUWMVLVFH-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 238000010526 radical polymerization reaction Methods 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 150000001491 aromatic compounds Chemical class 0.000 claims description 3
- 125000003636 chemical group Chemical group 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004400 mucous membrane Anatomy 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- DUDCYUDPBRJVLG-UHFFFAOYSA-N ethoxyethane methyl 2-methylprop-2-enoate Chemical compound CCOCC.COC(=O)C(C)=C DUDCYUDPBRJVLG-UHFFFAOYSA-N 0.000 description 10
- 229920001427 mPEG Polymers 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 206010009887 colitis Diseases 0.000 description 5
- 229960004132 diethyl ether Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000003999 initiator Substances 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 229940097156 peroxyl Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000000693 micelle Substances 0.000 description 4
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000002522 swelling effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001362 electron spin resonance spectrum Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WXFIFTYQCGZRGR-UHFFFAOYSA-N 5-hydroxy-2-methylhex-2-enamide Chemical compound CC(O)CC=C(C)C(N)=O WXFIFTYQCGZRGR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000011765 DBA/2 mouse Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960001479 tosylchloramide sodium Drugs 0.000 description 2
- 0 *C(*)(C*C1(*)*)*1=* Chemical compound *C(*)(C*C1(*)*)*1=* 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PQFMNVGMJJMLAE-QMMMGPOBSA-N L-tyrosinamide Chemical compound NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PQFMNVGMJJMLAE-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000001955 cumulated effect Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 239000012933 diacyl peroxide Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- LRPSOLYZVWRIEV-NSHDSACASA-N n-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LRPSOLYZVWRIEV-NSHDSACASA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000012966 redox initiator Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000003011 styrenyl group Chemical group [H]\C(*)=C(/[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to a polymeric preparation, which adjusts the internal environment of gastrointestinal tract (GIT) by removal of harmful substances, introduced into the GIT together with food or originated from processes taking place in GIT, mainly from inflammatory processes.
- GIT gastrointestinal tract
- the preparation has a beneficial influence on functioning of the mucose of the gastrointestinal tract and/or on inflammatory disease cure.
- GIT mucose Inner surfaces of GIT mucose are exposed to a very aggresive environment of gastrointestinal juices, characterized by extremely low pH values, enzymatic activity of gastrointestinal juices and actions of substances introduced into the GIT together with food.
- the inner surface of stomach wall and of other parts of GIT are covered by a layer of mucus, which has, among others, a protective function for the mucous membrane.
- a layer of mucus which has, among others, a protective function for the mucous membrane.
- stomach ulcers, Crohn disease and ulcerative colitis belong among the most frequent inflammatory diseases of GIT.
- ROS reactive oxygen free radicals
- Oxygen free radicals are for example hydroxyl, peroxyl and superoxide anionradicals. If the ROS concentration exceeds antioxidation capacity of the surrounding cells, the so-called oxidative stress occurs. The oxidative stress caused by ROS might cause further damage of the tissue, therefore worsen the overall progression of the inflammation, and importantly prolongate the course of treatment.
- CZ 293419 B6 relates to hydrophilic polymers in the form of a gel or a cover foil, which enhances the treatment process upon its application on a skin inflammation wound.
- the starting polymers contain a covalently bound sterically hindered amine or its oxidated derivative (nitroxide or hydroxylamine), which serve as very efficient free radical scavengers.
- Materials and preparations according to the above mentioned patent can be used on external injuries, wherein the localised effect is reached by applying the preparation directly on the injury.
- JP 2012-111700 A relates to polymeric antioxidants for use in GIT.
- the polymeric antioxidant is in the form of particles or micelles and contains derivatives of cyclic nitroxides in its structure.
- the described block copolymers contain chemically bound blocks of polyethylene glycol and polystyrene, whereas the polystyrene blocks contain styrene units functionalized in position 4 by functional groups capable of undergoing chemical modifications enabling introduction of cyclic nitroxides.
- a disadvantage of such solution is the binding of functional nitroxides on the polystyrene block of the copolymer, which forms the hydrophobic core of a micelle or a particle, respectively, therefore it is separated from its surroundings by a layer of polyethylene glycol which forms the hydrophilic coating of the micelle or the particle, respectively. It results in a limited accessibility of hydrophilic ROS to the antioxidant placed in the core of the micelle.
- Another factor influencing the progression of an inflammatory disease in GIT is the extremely low pH value, e.g. in stomach juices.
- Compounds chemically binding hydrochloric acid contained in stomach juices, can serve as a supporting agent to prevent the inflammation of the stomach mucous membrane and as a protection of the mucous membrane during the inflammatory stage (gastritis, irritated stomach, heartburn, reflux, gastroesophageal reflux disease, stomach ulcer and duodenum ulcer). It particularly concerns inorganic compounds based on bicarbonates, hydroxides, metal oxides (alluminium, magnesium), and optionally their combinations with omeprazole, which acts as a proton pump inhibitor. Low molecular weight compounds are usually dispersed in a polymeric carrier which swells in stomach juices and therefore ensures their controlled release into the surrounding medium.
- Object of the invention is a preparation for oral administration destined for prevention and treatment of inflammatory affections of the gastrointestinal tract.
- the preparation contains a biocompatible, hydrophilic polymer with affinity towards the glycoproteins present on the GIT mucous membrane surface, said polymer containing functional groups in its structure, which are able to bind harmful substances from the GIT juice.
- Individual functional components are covalently bound within polymeric chains, therefore they are effectively prevented from being released and absorbed into the bloodstream, which would lead to adverse systemic effects.
- Said polymer contains three types of structural units which have different functions in the polymeric structure and in the functioning of the preparation. Those structural units are: Structural units A, characterized by an ability to change their hydrophilic properties depending on the surrounding pH. These structural units ensure good solubility of the linear polymer, and, eventually, good swellability of branched and cross-linked polymeric structures in gastrointestinal tract juices in a wide range of pH (from 1.0 to 7.0). They are also able to adjust the pH of gastric fluid.
- Structural units B are selected from a group of compounds characterized by their affinity towards glycoproteins present on the gastrointestinal tract mucous membrane surface. The presence of such units in the polymeric structure enhances the adhesion of the polymer on the mucous membrane surface, and therefore keeps the active substance, incorporated in the polymeric chain, in contact with the afflicted site of the mucous membrane.
- Monomers suitable for providing affinity towards gastrointestinal tract mucous membrane surface are selected from hydroxy terminated (polyoxyethylene) acrylates and methacrylates, alkyloxy terminated (polyoxyethylene) acrylates and methacrylates, hydroxy terminated (polyoxyethylene) acrylamides and methacrylamides, alkyloxy terminated (polyoxyethylene) acrylamides and methacrylamides, preferably of an average molecular mass n in the range of 200 to 1000.
- the term “trustalkyl” means Ci-C 6 alkyls, if it is not stated otherwise.
- Salts include, in particular, salts of alkali metals and ammonium.
- Structural units C contain chemical groups capable of binding or inactivating substances which are toxic to the gastrointestinal tract or which negatively influence inflammatory processes.
- Suitable hydrophilic monomers capable of binding and inactivating free radicals are selected from a group of sterically hindered amines and their oxidated derivatives of general formula: wherein R 1 is -H or -OH or oxygen radical, R 2 to R 5 is (d - C4) alkyl, X is -CH(Y)- or - CH(Y)CH 2 - and Y is a chemical group capable of undergoing radical polymerization:
- R is -H or -C3 ⁇ 4 and Z is -O- or -NH-, whereas the content of structural units C in the polymer is at least 1 %, preferably from 3 to 30 mol.%.
- Structural units C are preferably derived from N-(2,2,6,6-tetramethylazinan-4-yl) methacrylamide or N-(2,2,6,6-tetramethylazinan-4-yl) methacrylate.
- the polymer contains up to 98 % of units A, from 1 to 99 % of units B and at least 1 % of units C (in molar %).
- Hydrophilic polymer according to the invention is prepared by radical polymerization of a mixture of precursors of structural units A, B and C.
- Initiators are used to initiate the radical copolymerization.
- Suitable initiators of the radical polymerization, as well as suitable polymerization procedures and conditions, are generally known to a skilled person.
- radical thermic initiators such as azoinitiators, diacylperoxides and other peroxocompounds, UV initiators generating free radicals by UV irradiation or redox initiators, generating free radicals by oxidation-reduction reaction, can be suitable. Initiation does not have to be limited by the types of initiators mentioned above.
- Polymers can be branched or crosslinked.
- Crosslinking reagents for the preparation of branched or crosslinked polymers can be, for example, ethylenedi(meth)acrylate, diglycol and oligoglycol acrylates and methacrylates, ethylendiamindi(meth)acrylate, l,l '-divinyl- 3,3'-(ethan-l,l '-diyl)bis(pyrrolidin-2-one), 2,3-dihydroxybutan-l,4-diyl diacrylate or dimethacrylate, N,N'-methylenebisacrylamide or other crosslinkers commonly used in the field.
- the hydrophilic polymer is, therefore, usually in the form of a high-molecular weight linear polymer, branched polymer or in the form of particles composed of covalently crosslinked gel. It is not absorbed by the gastrointestinal tract mucous membrane, neither does it enter the bloodstream, nor is it decomposed into low-molecular weight compounds which could be absorbed by the gastrointestinal tract. Non-absorbance of the polymer eliminates systemic contraindication. Moreover, the polymer is chemically neutral and does not undergo chain degradation in GIT juices.
- the hydrophilic polymer is soluble or it has a high swelling ability in GIT juices.
- the polymer upon its contact with juices of gastrointestinal tract, gradually swells, which makes the active structural units C, incorporated in polymeric chains, accessible.
- the polymer at the same time adheres to the gastrointestinal tract mucose because of the presence of structural units B, showing affinity towards mucose proteins.
- the active substance gets therefore in contact with the afflicted site of the mucous membrane; therewithal, the time for which the polymer (together with its active substance) rests in the particular part of the gastrointestinal tract is prolongated due to the adhesion of the polymer to the mucose.
- the preparation according to the present invention can preferably be in a form of a tablet (simple or multilayered, coated and non-coated, effervescent), capsule suitable for oral use, syrup, solution, emulsion or suspension.
- a tablet simple or multilayered, coated and non-coated, effervescent
- capsule suitable for oral use, syrup, solution, emulsion or suspension.
- the preparation can further contain other pharmaceutically acceptable auxiliary substances, for example excipients for easier tablet making, commonly used in the field; acid and base components ensuring the effervescent way of administration; disintegration agents, e.g. microcrystalline cellulose, starches (corn, potato and modified starches).
- disintegration agents e.g. microcrystalline cellulose, starches (corn, potato and modified starches).
- the content of disintegration agents in the preparation can reach up to 20 wt. %, preferably from 2 to 10 wt. %.
- Sweeteners can be used as auxiliary substances in order to mask the bitter taste of active compounds or to enhance the sweet taste of the dosage form.
- Sweeteners which can be used in the present invention, are selected from saccharides, such as monosaccharides or disaccharides (Z)-glucose, Z)-fructose, Z)-xylose, maltose, sucrose or sorbitol), polyols (glycerol, dulcitol, mannitol, sorbitol or xylitol), artificial sweeteners (saccharin and its sodium, potassium or calcium salts, cyclamate and its sodium or calcium salt, aspartame, acesulfame or their potassium salts).
- the content of sweeteners in the preparation can range from 2 to 60 wt. %, preferably from 5 to 10 wt. % (relative to the weight of the dosage form).
- the auxiliary substances can include also aromatic compounds, which can be used in the present invention and which are not limited to the following examples: e.g., orange, lemon or grape flavour, peppermint flavour etc.
- the aromatic compounds can be used in the range of 0.01 to 5 wt. % (relative to the weight of the dosage form).
- the polymer structure is designed to enable preferential concentration of the preparation close to the gastrointestinal tract mucose, e.g. utilising the adhesion of the preparation towards the mucose surface.
- the protective effect of the preparation towards the gastrointestinal tract mucose is enhanced by its adhesion to the mucose, the adjustment of the local pH in the mucose proximity or by protection of the mucose cells against harmful substances.
- the preparation includes chemical structures which specifically bind harmful substances of gastrointestinal tract juices, e.g. structures which bind and inactivate free radicals, structures adjusting pH of the gastric fluid by binding hydrochloric acid etc. Functional structures specifically binding harmful substances are covalently incorporated into the material of the preparation.
- the present invention is a polymeric preparation composed of copolymers, in which different types of hydrophilic units (A, B, C) are statistically incorporated into the whole length of the polymeric chain. It ensures an even swelling of the polymer, which highly enhances the accessibility of the bound ROS antioxidant and enables molecules of the antioxidant to act in a close proximity of the mucose surface.
- Another advantage of the present invention is the method of incorporating the molecules of antioxidants into the polymer by radical copolymerization, in which the antioxidant acts as comonomer. It simplifies the production of the preparation on industrial scale, which increases the industrial applicability of the invention.
- Fig. 1 Time dependence of relative fluorescence intensity of the reaction mixture containing peroxyl free radicals and the polymer according to Example 4.
- the curve a corresponds to the reference sample without polymer
- curves b, c, d, e correspond to samples containing 5 mg, 10 mg, 20 mg and 40 mg of the polymer.
- Fig. 2 EPR spectrum of the polymer solution according to Example 5, after the reaction with in situ generated peroxyl free radicals.
- Fig. 3 In vivo imaging of three mice 2 h, 5 h and 12 h after p.o. application of polymer solution labeled according to Example 8 (ca 50 MBq/mouse).
- Fig. 4 Ex vivo biodistribution of the polymer according to Example 8 in DBA/2 mice; 2 h, 6 h and 24 h after the p.o. application, expressed as a percentage of the total dosage (% ID).
- Fig. 5 A part of a large intestine of a BALB/c mouse before (left) and after the exposure to the ABC polymer suspension (right) under UV light.
- Fig. 7 Time dependence of the relative fluorescence intensity of the reaction mixture containing hydroxyl free radicals and the polymeric network according to Example 14.
- the continuous curve corresponds to a blank sample, other dependences belong to samples with polymer concentrations of 0.9 mg/mL ( ⁇ ), 4.5 mg/mL (A) and 9.0 mg/mL (o).
- Fig. 9 Development of average weight of mice tested in individual groups in the course of the treatment described in Example 20.
- Example 5 Antioxidation ability of a solution of the linear polymer obtained in Example 4 was determined against in situ generated peroxyl radicals. The experiment was as follows: Stock buffered solutions of the polymer at concentrations 8 mg/mL, 16 mg/mL, 32 mg/mL and 64 mg/mL were prepared. In each vial, 650 ⁇ ⁇ of the polymer stock solution was placed together with 1.3 mL of fluorescein solution (2.4 x 10 "5 M) and 1.95 mL of AAPH solution (0,16 M). Directly after addition of all components, a continuous decrease of fluorescence intensity was measured during 60 minutes at 37 °C. The measurement was repeated twice for each polymer concentration. Fig. 1 shows that the polymer at the above mentioned conditions acts as a very efficient peroxyl radical scavenger.
- Example 6 shows that the polymer at the above mentioned conditions acts as a very efficient peroxyl radical scavenger.
- EPR spectrum of the polymer solution from Example 5 was measured after a reaction with peroxyl radicals (Fig. 2). EPR spectrum confirmed the presence of the oxidated form of a sterically hindered amine.
- radioisotope I according to the following procedure:
- the radioactivity was measured in the organs using an automatic gamma counter. The results were expressed as percentages of the originally applied dose (% ID). The ex vivo biodistribution study confirmed a complete elimination of the polymer via the gastrointestinal tract (Fig. 4).
- the precipitated polymer (ABC) was filtered off, extracted by dioxane and dried into a constant weight. Analogical procedure was used to prepare a polymeric sample (AC), which does not contain the structural unit based on poly(ethyleneglycol) methyl ether methacrylate.
- Antioxidation capacity against in situ generated hydroxyl free radicals in solution of the polymer network prepared in Example 15 was determined, according to the following procedure. Eight Eppendorf tubes containing appropriate amounts of the polymer were placed into a thermoblock and tempered to 37 °C. Then 900 ⁇ ⁇ of a buffer, 200 ⁇ ⁇ of Na 2 W0 4 .2 H 2 0 solution in a buffer (7.3 mM), 10 iL of fluorescein solution (2.4 x 10 "5 M) were placed into each tube and the polymer was kept to swell in this mixture for 5 minutes. Hydroxyl radical generation was started by an addition of 10 ⁇ ⁇ of hydrogen peroxide solution. The tubes were shaken and tempered to 37 °C during the whole time of the reaction.
- Example 20
- Example 15 The therapeutic effect of the preparation prepared in Example 15 in the GIT was performed with the Balb/C induced chronic colitis experimental model.
- mice 20 male Balb/C mice were divided into three groups:
- DSS sodium dextran sulfate
- Fig. 9 shows the comparison of average weight of mice in individual groups during the course of the treatment. There is a clearly visible difference between the N group and the L group which shows slowing down (or even reversing) of the pathological process in the L group.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2963582A CA2963582C (en) | 2014-11-28 | 2015-11-20 | Oral preparation comprising mucoadhesive, biocompatible hydrophilic polymer for preventing and/or treating inflammatory conditions of the gastrointestinal tract |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ2014-825A CZ2014825A3 (cs) | 2014-11-28 | 2014-11-28 | Přípravek pro orální použití |
CZPV2014-825 | 2014-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016082808A1 true WO2016082808A1 (en) | 2016-06-02 |
Family
ID=54054181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2015/050011 WO2016082808A1 (en) | 2014-11-28 | 2015-11-20 | Oral preparation |
Country Status (3)
Country | Link |
---|---|
CA (1) | CA2963582C (cs) |
CZ (1) | CZ2014825A3 (cs) |
WO (1) | WO2016082808A1 (cs) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ308047B6 (cs) * | 2018-07-17 | 2019-11-20 | Ústav makromolekulární chemie AV ČR, v. v. i. | Tekutý krycí přípravek pro ošetření ran |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999028359A1 (en) * | 1997-12-03 | 1999-06-10 | Ústav Makromolekulární Chemie Akademie Ved C^¿Eské Republiky | Preparation for prevention and healing of inflammation affections |
JP2012111700A (ja) | 2010-11-22 | 2012-06-14 | Univ Of Tsukuba | 高分子化環状ニトロキシドラジカル化合物の潰瘍性消化管の炎症の処置剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009133647A1 (ja) * | 2008-05-02 | 2009-11-05 | 国立大学法人筑波大学 | 高分子化環状二トロキシドラジカル化合物およびその使用 |
CZ2008490A3 (cs) * | 2008-08-15 | 2010-02-24 | Labský@Jirí | Synergický vliv benzofenonu a stericky stínených aminu pri lécení povrchových poranení |
JP2013173689A (ja) * | 2012-02-24 | 2013-09-05 | Univ Of Tsukuba | 高分子化ニトロキシドラジカル化合物と非ステロイド性抗炎症薬の複合体 |
-
2014
- 2014-11-28 CZ CZ2014-825A patent/CZ2014825A3/cs unknown
-
2015
- 2015-11-20 CA CA2963582A patent/CA2963582C/en active Active
- 2015-11-20 WO PCT/CZ2015/050011 patent/WO2016082808A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999028359A1 (en) * | 1997-12-03 | 1999-06-10 | Ústav Makromolekulární Chemie Akademie Ved C^¿Eské Republiky | Preparation for prevention and healing of inflammation affections |
CZ293419B6 (cs) | 1997-12-03 | 2004-04-14 | Ústav Makromolekulární Chemie Av Čr | Přípravek k prevenci a hojení zánětlivých onemocnění |
JP2012111700A (ja) | 2010-11-22 | 2012-06-14 | Univ Of Tsukuba | 高分子化環状ニトロキシドラジカル化合物の潰瘍性消化管の炎症の処置剤 |
Non-Patent Citations (3)
Title |
---|
DONG ZHANG ET AL: "Synthesis and Solubility of (Mono-) End-Functionalized Poly(2-hydroxyethyl methacrylate- g -ethylene glycol) Graft Copolymers with Varying Macromolecular Architectures", MACROMOLECULES, vol. 38, no. 6, 1 March 2005 (2005-03-01), US, pages 2530 - 2534, XP055252484, ISSN: 0024-9297, DOI: 10.1021/ma049330k * |
L. POLÁKOVÁ ET AL: "Antioxidant Properties of 2-Hydroxyethyl Methacrylate-Based Copolymers with Incorporated Sterically Hindered Amine", BIOMACROMOLECULES, vol. 16, no. 9, 14 September 2015 (2015-09-14), US, pages 2726 - 2734, XP055252383, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.5b00599 * |
SERRA L ET AL: "Design of poly(ethylene glycol)-tethered copolymers as novel mucoadhesive drug delivery systems", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 63, no. 1, 1 May 2006 (2006-05-01), pages 11 - 18, XP027998014, ISSN: 0939-6411, [retrieved on 20060501], DOI: 10.1016/J.EJPB.2005.10.011 * |
Also Published As
Publication number | Publication date |
---|---|
CA2963582A1 (en) | 2016-06-02 |
CA2963582C (en) | 2017-12-05 |
CZ305391B6 (cs) | 2015-08-26 |
CZ2014825A3 (cs) | 2015-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Duong et al. | The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension | |
Sinha et al. | Capecitabine encapsulated chitosan succinate-sodium alginate macromolecular complex beads for colon cancer targeted delivery: In vitro evaluation | |
Foss et al. | Development of acrylic-based copolymers for oral insulin delivery | |
Bailly et al. | Poly (N-vinylpyrrolidone)-block-poly (vinyl acetate) as a drug delivery vehicle for hydrophobic drugs | |
Van der Merwe et al. | Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs | |
Shah et al. | RETRACTED ARTICLE: pH-responsive CAP-co-poly (methacrylic acid)-based hydrogel as an efficient platform for controlled gastrointestinal delivery: fabrication, characterization, in vitro and in vivo toxicity evaluation | |
JP2000517356A (ja) | 併発胆汁酸吸着作用を有する高分子量胆汁酸吸収阻害剤 | |
CA2175479A1 (en) | Drug delivery systems | |
BR112013025519B1 (pt) | Composição farmacêutica e seu processo de preparação | |
BRPI0209134B1 (pt) | uso de um sevelamer ou um sal do mesmo e uso de um colesevelam ou um sal do mesmo | |
Singh et al. | Development of novel hydrogels by functionalization of sterculia gum for use in anti-ulcer drug delivery | |
Jin et al. | Vitamin B12 diffusion and binding in crosslinked poly (acrylic acid) s and poly (acrylic acid-co-N-vinyl pyrrolidinone) s | |
Yao et al. | Nano-enabled delivery of EGCG ameliorates silica-induced pulmonary fibrosis in rats | |
Polakova et al. | SHARP hydrogel for the treatment of inflammatory bowel disease | |
Suhail et al. | Fabrication, characterization and toxicological evaluation of polyethylene glycol/sodium polystyrene sulfonate hydrogels for controlled delivery of Acetaminophen | |
Farid-ul-Haq et al. | A pH-responsive Artemisia vulgaris mucilage-co-acrylic acid hydrogel: Synthesis, characterization, controlled drug release, toxicity studies, and MRI | |
CA2963582C (en) | Oral preparation comprising mucoadhesive, biocompatible hydrophilic polymer for preventing and/or treating inflammatory conditions of the gastrointestinal tract | |
Febrianti et al. | Development of pH-sensitive nanoparticle incorporated into dissolving microarray patch for selective delivery of methotrexate | |
CZ293419B6 (cs) | Přípravek k prevenci a hojení zánětlivých onemocnění | |
CN108976356B (zh) | 一种由联硒键连接的温度、氧化还原敏感型药物递送材料及其制备和应用 | |
Tuesca et al. | Complexation hydrogels for oral insulin delivery: effects of polymer dosing on in vivo efficacy | |
Hu et al. | Hydrophilic polymer driven crystallization self-assembly: an inflammatory multi-drug combination nanosystem against Alzheimer’s disease | |
Averick et al. | Green anchors: Chelating properties of ATRP-click curcumin-polymer conjugates | |
Zhao et al. | Supramolecular nanoparticle loaded with bilirubin enhances cartilage protection and alleviates osteoarthritis via modulating oxidative stress and inflammatory responses | |
Ali et al. | Radiation synthesis of poly (ethylene glycol)/acrylic acid hydrogel as carrier for site specific drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15817056 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2963582 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15817056 Country of ref document: EP Kind code of ref document: A1 |